Elite in Mevalonate Kinase Deficiency

Jordi F. Anton

Barcelona, CT, ES 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Mevalonate Kinase Deficiency
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Jordi Anton practices in Barcelona, Spain. Anton is rated as an Elite expert by MediFind in the treatment of Mevalonate Kinase Deficiency. Their top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Mevalonate Kinase Deficiency, Kawasaki Disease, Scleroderma, and Bone Marrow Aspiration.

Their clinical research consists of co-authoring 152 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 9 articles in the study of Mevalonate Kinase Deficiency.

Locations

Barcelona, CT, Spain
Other Locations
Sant Joan Despi, CT, Spain
Esplugues De Llobregat, CT, Spain
Vilafranca Del Penedes, CT, Spain
Sant Joan, PM, Spain
Valencia, VC, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes
Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes
Enrollment Status: Recruiting
Publish Date: November 30, 2023
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drugs: Ixekizumab, Adalimumab
Study Phase: Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Pilot, Open-label, Single Arm, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
A Pilot, Open-label, Single Arm, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)
Enrollment Status: Completed
Publish Date: May 17, 2022
Intervention Type: Drug
Study Drug: Emapalumab Anti-IFN-Gamma Antibody
Study Phase: Phase 2
View 3 Less Clinical Trials

152 Total Publications

Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach.
Improving care for children with juvenile idiopathic arthritis: the role of IL-6 inhibitors in a patient-centered approach.
Journal: Expert opinion on biological therapy
Published: October 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Anton's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 22 Advanced Conditions
View All 44 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile